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An important aspect of cancer therapy is main-
taining  a  fine  balance  between  the  use  of 
chemoradiotherapy doses high enough to kill 
tumor cells and doses low enough to prevent 
damage to normal tissue. The gastrointestinal 
(GI) epithelium and BM are the most rapidly 
self-renewing tissues in adults and are therefore 
susceptible  to  cytotoxic  exposure,  showing  a 
rapid expression of damage. Damage to these 
tissues is a dose-limiting and potentially lethal 
toxicity  of  chemoradiotherapy  used  to  treat 
cancer patients. Allogeneic hematopoietic stem 
cell transplantation (SCT) is a curative therapy 
for  hematologic  malignancies  that  works  by 
delivering healthy hematopoietic stem cells   
to  replace  BM  destroyed  by  the  high-dose 
chemoradiotherapy (pretransplant conditioning);   
however, this process is complicated by regimen- 
related toxicity against other tissues, particularly 
in the GI tract.
Graft-versus-host disease (GVHD), a major 
and devastating complication of allogeneic SCT, 
is a complex process involving donor T cell re-
sponses to host antigens and the dysregulation 
of inflammatory cytokine cascades (Hill et al., 
1997;  Hill  and  Ferrara,  2000; Teshima  et  al., 
2002a; Ferrara et al., 2003). Increasing evidence 
from experimental and clinical SCT suggests 
that  conditioning-mediated  GI  tract  damage 
plays a central role in amplifying GVHD by 
propagating its cytokine storm characteristics 
(Hill et al., 1997; Hill and Ferrara, 2000; Ferrara 
et al., 2003). Intestinal epithelial cells are con-
tinuously regenerated from intestinal stem cells 
(ISCs), which are key to the regeneration of 
damaged intestinal epithelium (Batlle et al., 
2002; Pinto et al., 2003; Barker et al., 2007, 
2008). However, the dynamic process of damage 
and repopulation of ISCs, which play a pivotal 
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Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow 
transplantation (BMT), and damage to the gastrointestinal (GI) tract plays a critical role in 
amplifying systemic disease. Intestinal stem cells (ISCs) play a pivotal role not only in 
physiological tissue renewal but also in regeneration of the intestinal epithelium after 
injury. In this study, we have discovered that pretransplant conditioning regimen damaged 
ISCs; however, the ISCs rapidly recovered and restored the normal architecture of the 
intestine. ISCs are targets of GVHD, and this process of ISC recovery was markedly inhibited 
with the development of GVHD. Injection of Wnt agonist R-spondin1 (R-Spo1) protected 
against ISC damage, enhanced restoration of injured intestinal epithelium, and inhibited 
subsequent inflammatory cytokine cascades. R-Spo1 ameliorated systemic GVHD after 
allogeneic BMT by a mechanism dependent on repair of conditioning-induced GI tract 
injury. Our results demonstrate for the first time that ISC damage plays a central role in 
amplifying systemic GVHD; therefore, we propose ISC protection by R-Spo1 as a novel 
strategy to improve the outcome of allogeneic BMT.
© 2011 Takashima et al.  This article is distributed under the terms of an   
Attribution–Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first 
six  months  after  the  publication  date  (see  http://www.rupress.org/terms).   
After six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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our preliminary experiments (unpublished data), mice irra-
diated with 15 Gy TBI on day 0 were intravenously injected 
with 200 µg R-Spo1 once daily from day 3 to 1 and from 
day 1–3. The real-time PCR analysis of the small intestine 
harvested 6 h after the final administration of R-Spo1 showed 
up-regulated  expression  of  Axin2  and  Ascl2  in  R-Spo1–
treated mice (Fig. 1 A). The Olfm4+ cell population was signifi-
cantly greater in R-Spo1–treated mice than in controls on 
day 3 (Fig. 1, B and C); as a result, radiation colitis characterized 
role in the competitive race between tissue damage and   
restoration during conditioning regimens and GVHD, is not 
well understood.
Wnt signaling plays a critical role in the regulation of in-
testinal epithelial cell proliferation during their maturation or 
regeneration (Batlle et al., 2002; Pinto et al., 2003; Reya and 
Clevers, 2005; Barker et al., 2008). R-spondin1 (R-Spo1) is a 
potent activator of the Wnt signaling pathway. It relieves the 
Dickkopf-1 inhibition imposed on the Wnt signaling path-
way and thereby increases levels of the Wnt pathway corecep-
tor low-density lipoprotein receptor–related protein-6 on cell 
surface (Kim et al., 2005; Binnerts et al., 2007). We have previ-
ously shown that human R-Spo1 transgenic mice had a marked 
thickening of the mucosa and displayed crypt epithelial   
hyperplasia (Kim et al., 2005). Injection of human R-Spo1 
induced rapid onset of crypt cell proliferation in the intestine 
of normal mice through -catenin stabilization and sub-
sequent transcriptional activation of target genes (Kim et al., 
2005). Thus, injection of R-Spo1 protected mice from chemo-
therapy- or radiation-induced colitis by stimulating mucosal 
regeneration and restoring intestinal architecture (Kim et al., 
2005; Zhao et al., 2007, 2009; Bhanja et al., 2009). However, 
because of the lack of specific markers for ISCs, it is unclear 
whether this result was mediated by the direct effect of   
R-Spo1 on ISCs.
In this study, we investigated the dynamic process of ISC 
damage and repopulation during the pretransplant conditioning 
regimen, total body irradiation (TBI), and GVHD. The effects   
of R-Spo1 on this process were also examined using recently 
identified  markers  for  ISCs  such  as  Lgr5  (leucine-rich  repeat– 
containing G protein–coupled receptor 5) and Olfm4 (Olfactomedin-4; 
Barker et al., 2007, 2008; van der Flier et al., 2009a,b). Lgr5 
and Olfm4 mark rapidly cycling crypt base columnar cells, 
which can give rise to all intestinal epithelial lineages (Barker 
et al., 2007, 2008; van der Flier et al., 2009a,b). We then tested 
the hypothesis that protection of ISCs improves the outcome 
of allogeneic SCT by regulating systemic GVHD using a well-
characterized murine model of MHC-mismatched, haploi-
dentical BM transplantation (BMT).
RESULTS
R-Spo1 protected against radiation-induced colitis  
by stimulating proliferation of ISCs through the Wnt 
signaling pathway
We first studied the effect of R-Spo1 on the expression of 
Wnt target genes in the small intestine using quantitative real-
time PCR. Injection of R-Spo1 (200 µg/day) over 3 d sig-
nificantly  up-regulated  the  expression  of Wnt  target  genes, 
including Axin2, Ascl2 (Achaete scute-like 2), and Lgr5 (Fig. S1 A). 
We noted an elongation of villi with an increased number of 
Olfm4+ ISCs in the crypts of R-Spo1–treated animals (Fig. S1, 
B and C). Ki-67 immunostaining also showed crypt hyper-
plasia paralleling an increased number of Ki-67+ cycling cells 
in the crypts (Fig. S1, D and E).
Next, we evaluated the effect of R-Spo1 administration 
on the process of mucosal regeneration after TBI. According to 
Figure 1.  R-Spo1 protected against radiation-induced colitis by 
enhancing proliferation of ISCs via the Wnt signaling pathway. 
B6D2F1 mice irradiated with 15 Gy TBI on day 0 and intravenously in-
jected with R-Spo1 (200 µg/day) or control from day 3 to 1 and day 
1–3. The small intestine was harvested 6 h after the final administration 
of R-Spo1 for quantitative real-time PCR analysis and in situ hybridiza-
tion, and 24 h later for immunohistochemistry. (A) Quantitative real-time 
PCR analysis of Axin2, Ascl2, and Lgr5 transcripts normalized to those of 
GAPDH (naive, n = 3; control, n = 4; R-Spo1, n = 4). (B) In situ hybridiza-
tion for Olfm4 on representative crypts. (C) Quantification of Olfm4+ cells 
per crypt (n = 4 per group). (D) Ki-67 staining of the terminal ileum.  
(E) Villus height of the terminal ileum (naive, n = 3; control, n = 4; R-Spo1,  
n = 4). (F) Quantification of Ki-67+ cells per crypt (naive, n = 3; control,  
n = 4; R-Spo1, n = 4). Data are representative of two independent experi-
ments and are shown as means ± SD. *, P < 0.05 compared with control. 
Bars: (B and D, top row) 100 µm; (B and D, bottom row) 20 µm.JEM VOL. 208, February 14, 2011 
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crucial for the regeneration of damaged intestinal epithelium 
and also how the damage and repopulation of ISCs affects the 
process of mucosal injury and regeneration after allogeneic 
BMT. To address these issues, lethally irradiated B6D2F1 mice 
were transplanted with 5 × 106 T cell–depleted (TCD) BM 
cells with or without 2 × 106 T cells from MHC-mismatched 
C57BL/6 (B6) or B6-Ly5.1 donors on day 0. Small intestines 
were harvested from mice on day 0 before TBI and on days 3 
and 6 after BMT, and quantitative real-time PCR and in situ 
hybridization were performed to determine the kinetics of 
loss and repopulation of Olfm4+ ISCs. R-Spo1 was injected 
from day 3 to 1 and day 1–3 after BMT. TCD animals and 
control-treated allogeneic animals served as non-GVHD 
by blunting of villi was significantly reduced in R-Spo1–
treated animals (Fig. 1, D and E). We also noted crypt hyper-
plasia and an increased number of Ki-67+ cycling cells in the 
crypt on day 4 (Fig. 1, D and F). These results extend our pre-
vious observations regarding R-Spo1–mediated mitogenic 
effects on the intestinal epithelium (Kim et al., 2005) by docu-
menting the effects of R-Spo1 on ISCs.
R-Spo1 protected against ISC damage after allogeneic BMT
GI tract damage is much more severe in allogeneic SCT than 
in autologous or syngeneic SCT because of the additional 
detrimental effects of GVHD on the GI tract. However, it re-
mains to be elucidated whether GVHD targets ISCs that are 
Figure 2.  R-Spo1 enhanced repopulation of ISCs after allogeneic BMT. Lethally irradiated B6D2F1 mice were transplanted with 5 × 106 TCD BM 
with or without 2 × 106 T cells from B6 donors on day 0. R-Spo1 (200 µg/day) or control was intravenously injected from day 3 to 1 and day 1–3 
after BMT. Small intestines were harvested on day 0 (before TBI) and days 3 and 6. (A) Quantitative real-time PCR analysis of Olfm4 transcripts normalized 
to those of GAPDH (TCD, n = 3; control, n = 4; R-Spo1, n = 4 per time point). (B) In situ hybridization of Olfm4 on representative crypts. (C) Quantification 
of Olfm4+ cells per crypt (TCD, n = 3; control, n = 4; R-Spo1, n = 4 per time point). (D) Ki-67 staining of the terminal ileum harvested on day 6. (E) Villus 
height of the terminal ileum was measured as described in Fig. 1 E using the slides in D (TCD, n = 3; control, n = 5; R-Spo1, n = 5). (F) Quantification of 
Ki-67+ cells per crypt (TCD, n = 3; control, n = 5; R-Spo1, n = 5). Data are representative of two independent experiments and are shown as means ± SD. 
*, P < 0.05 compared with control. Bars: (B and D, top rows) 100 µm; (B and D, bottom rows) 20 µm.288 R-spondin1 ameliorates GVHD | Takashima et al.
and  that  the  process  of  ISC  repopulation  is  inhibited  in 
GVHD. In R-Spo1–treated animals, the number of Olfm4+ 
cells was consistently higher before and after BMT than that 
in allogeneic controls. Villous atrophy was severe in allogeneic 
controls on day 6, whereas injection of R-Spo1 resulted in 
crypt hyperplasia with an increased number of Ki-67+ cycling 
cells in the crypts and dramatically ameliorated GI tract dam-
age (Fig. 2, D–F). R-Spo1 treatment before TBI thus ex-
panded the ISC pool and minimized intestinal damage.
R-Spo1 suppressed inflammatory cytokine cascades  
and donor T cell activation after allogeneic BMT
We then tested the hypothesis that protection of ISCs against 
TBI regulates systemic GVHD and improves the outcome of 
controls and GVHD controls, respectively. In both groups, 
Olfm4 expression levels significantly decreased in the small 
intestine on day 3 (Fig. 2 A). In TCD animals, Olfm4 expres-
sion recovered to normal levels on day 6, whereas in alloge-
neic controls, it remained low. In contrast, Olfm4 expression 
levels in R-Spo1–treated animals were significantly higher on 
and after day 0 in comparison with allogeneic controls (Fig. 2 A). 
These results were further confirmed by in situ hybridization 
analysis of Olfm4 transcripts in the small intestine. The Olfm4+ 
ISC population significantly decreased in both TCD and al-
logeneic controls on day 3 (Fig. 2, B and C). On day 6, Olfm4+ 
cells were fully repopulated in TCD animals, and their num-
bers were significantly higher than their numbers in alloge-
neic controls. These results demonstrate that TBI injures ISCs 
Figure 3.  R-Spo1 regulated activation of inflammatory and cellular effectors in GVHD. Lethally irradiated B6D2F1 mice were transplanted with 
5 × 106 TCD BM cells with or without 2 × 106 T cells from B6-Ly5.1 (CD45.1+) donors on day 0. R-Spo1 (200 µg/day) or control was intravenously injected 
from day 3 to 1 and day 1–3 after BMT. Serum samples and splenocytes were obtained 5–7 d after BMT (TCD, n = 3; control, n = 5; R-Spo1, n = 5). 
(A–C) Serum levels of LPS (A), TNF (B), and IFN- (C) are shown. (D–G) Numbers of donor (CD45.1+) T cells (D), CD69+ donor T cells (E), IFN-+ donor T cells (F),  
and CD4+CD25+Foxp3+ T reg cells (G) in spleen are shown. (H–K) Flow cytometric analysis and enumeration of T cell subsets in spleen. Numbers represent 
the percentage of cells in the dot plot quadrants. CD8+ T cells (H and I) and CD4+ T cells (J and K) are shown. Data are representative of two independent 
experiments and are shown as means ± SD. *, P < 0.05 compared with control. U.D., undetectable.JEM VOL. 208, February 14, 2011 
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and the addition of R-Spo1 to culture did not affect in vitro 
T cell responses to alloantigens or anti-CD3 cross-linking 
(Fig. S2, A and B). Furthermore, R-Spo1 addition to culture 
affected neither the proliferation nor the generation of effec-
tor and memory CD8+ and CD4+ T cells in response to anti-
CD3 cross-linking in vitro (Fig. S2, C–F).
Brief administration of R-Spo1 ameliorated systemic GVHD
We studied two lethal doses of TBI, 12 and 15 Gy, for their 
effects on GVHD. At both TBI doses, TCD controls showed 
100% survival. All allogeneic controls receiving 15 Gy TBI 
died by day 40, whereas those receiving 12 Gy TBI displayed 
7% survival at day 90 (Fig. 4 A). The TBI dose thus signifi-
cantly correlated with GVHD mortality, as has been shown 
previously  (Hill  et  al.,  1997).  In  R-Spo1–treated  animals, 
GVHD mortality was significantly reduced in experiments 
with 12 Gy TBI and delayed in those with 15 Gy TBI (Fig. 4 A) 
and reduced GVHD severity as assessed by clinical GVHD 
scores (Teshima et al., 2002a) in surviving animals (Fig. 4 B). 
Target organs, including the small intestine, liver, skin, and 
thymus, were then evaluated for signs of GVHD after alloge-
neic BMT after 12 Gy TBI. The small intestine and liver sam-
ples were harvested 1 wk after BMT, whereas skin and thymus 
samples were obtained 7 wk after BMT. GVHD-mediated 
thymic atrophy, characterized by a reduction in the numbers 
of CD4+CD8+ double-positive thymocytes, was significantly 
restored  in  R-Spo1–treated  mice  (Fig.  4  C).  Pathological 
analysis of the small intestine, liver, and skin showed almost 
normal architecture in TCD controls (Fig. 4 D). In contrast, 
allogeneic  controls  showed  severe  blunting  of  villi  and   
inflammatory  infiltration,  whereas  R-Spo1–treated  mice 
showed significant restoration of the small intestinal villous 
architecture with little inflammatory infiltration. Liver histol-
ogy of allogeneic controls revealed mononuclear cell infiltra-
tion in bile ducts and portal triads (Fig. 4 D, arrowheads), 
whereas these changes were less prominent in R-Spo1–treated 
mice. Lesser lymphocyte infiltration was observed in the skin 
of R-Spo1–treated mice compared with that of allogeneic 
controls. GVHD pathology scores in each organ were signifi-
cantly lower in R-Spo1–treated mice than those in controls 
(Fig. 4, E–G). Flow cytometric analysis of the spleens on day 
35 displayed complete donor chimerism (99.9 ± 0.1%), ruling 
out mixed chimerism as a cause of the reduced GVHD. These 
results demonstrate that brief administration of R-Spo1 mod-
ulates not only intestinal but also systemic GVHD.
Next, we studied how the scheduling of R-Spo1 administra-
tion  could  influence  the  outcome  of  allogeneic  BMT  after   
15 Gy TBI. Administration of R-Spo1 from day 3 to 1 and 
day 1–3 significantly prolonged survival. These beneficial effects 
were not observed when R-Spo1 was injected only once   
after BMT from day 1–6 after 15 Gy TBI (Fig. 4 H). When 
R-Spo1 was administered only once before TBI from day 6 
to 1, early GVHD mortality was reduced; however, survival 
was not prolonged. These results suggest that R-Spo1 injec-
tion before TBI is mandatory and that posttransplant adminis-
tration of R-Spo1 results in maximum reduction of GVHD.
allogeneic SCT. Serum LPS levels are increased during GVHD 
and correlate with GI tract damage (Hill et al., 1997; Hill and 
Ferrara, 2000; Ferrara et al., 2003). LPS has been shown to 
stimulate production of excessive inflammatory cytokines 
such as TNF that are implicated in the pathogenesis of GVHD 
(Nestel et al., 1992; Hill et al., 1997; Hill and Ferrara, 2000; 
Cooke et al., 2001; Teshima et al., 2002a; Ferrara et al., 2003). 
LPS and TNF levels were markedly increased in allogeneic 
controls but were significantly reduced in R-Spo1–treated 
animals (Fig. 3, A and B), suggesting that the fortification of 
GI mucosal barrier functions by R-Spo1 suppresses subse-
quent inflammatory cascades in GVHD. We also investigated 
the effect of R-Spo1 on allogeneic donor T cell responses. 
Serum levels of IFN-, a hallmark of systemic T cell responses 
in GVHD, were significantly lower in R-Spo1–treated mice 
than in controls (Fig. 3 C). Donor T cell expansion (Fig. 3 D) 
and activation, as determined by CD69 expression (Fig. 3 E), 
and intracellular IFN- (Fig. 3 F) were also significantly re-
duced in R-Spo1–treated mice. Recent studies have shown 
that Wnt signaling can modulate adoptive immunity by en-
hancing regulatory T cell (T reg cell) survival and inducing 
CD4+ T cell anergy, as well as by regulating effector CD8+  
T cell development and promoting memory CD8+ T cell 
generation (Ding et al., 2008; Gattinoni et al., 2009). However,   
in our study, the number of CD4+CD25+Foxp3+ T reg cells in 
the spleen was significantly less in R-Spo1–treated mice than 
in controls (Fig. 3 G), and the ratios of effector to memory 
CD8+ (Fig. 3, H and I) and CD4+ T cells (Fig. 3, J and K) were 
similar between R-Spo1–treated mice and controls.
To  further  confirm  whether  the  reduction  in  donor   
T cell activation after BMT was caused by the direct effect of 
R-Spo1 on T cells, we investigated the effect of R-Spo1 on   
T cells in vivo and in vitro. Administration of R-Spo1 over 3 d 
had no effect on the number of T cells in naive mice (Table I), 
Table I.  Brief administration of R-Spo1 had no effects  
on immunophenotype
Immunophenotype +Control +R-Spo1
Spleen
CD4+ 20.7 ± 4.2 17.4 ± 2.0
CD8+ 14.3 ± 2.5 11.9 ± 0.9
CD4+Foxp3+ 2.46 ± 0.63 2.46 ± 0.34
B220+ 58.5 ± 10.9 57.8 ± 2.9
Mesenteric lymph node
CD4+ 4.3 ± 0.7 4.9 ± 0.2
CD8+ 3.5 ± 0.7 4.2 ± 0.4
CD4+Foxp3+ 0.65 ± 0.14 0.70 ± 0.09
Thymus
CD4+CD8+ 96.2 ± 16.9 91.6 ± 19.8
CD4+ 8.4 ± 1.0 8.6 ± 2.1
CD8+ 3.4 ± 0.3 3.6 ± 0.6
B6 mice were intravenously injected with R-Spo1 (200 µg/day) or control for 3 d, 
and the spleen, mesenteric lymph nodes, and thymus were harvested 6 h later.  
Cell numbers are shown as mean ± SD (×106). Data are representative of two 
independent experiments (n = 4 for +control and +R-Spo1).290 R-spondin1 ameliorates GVHD | Takashima et al.
thymic  GVHD  (Fig.  5  D),  GVHD-associated  cytopenia   
(Fig. 5 E), or donor cell engraftment (99.7 ± 0.4% in controls 
and 99.9 ± 0.0% in R-Spo1–treated mice on day 60).
DISCUSSION
Intestinal GVHD is characterized by severe villous atrophy 
and crypt degeneration. It has been suggested that crypt cell 
degeneration is one of the initial lesions of intestinal GVHD 
(Sale et al., 1979; Epstein et al., 1980; Mowat and Socie, 2004). 
ISCs reside in the intestinal crypts and play a pivotal role in 
both physiological tissue renewal and regeneration of the   
intestinal epithelium after injury. However, the identity of 
cells within the crypts (primary targets in GVHD) has been an 
R-Spo1 regulates GVHD by a mechanism dependent  
on repair of radiation-induced gut injury
To confirm that R-Spo1 ameliorated systemic GVHD by a 
mechanism  dependent  on  repair  of  radiation-induced  GI 
tract damage, the effects of R-Spo1 were evaluated in the 
same BMT model without conditioning, as previously de-
scribed (Mori et al., 1998). Unirradiated B6D2F1 mice were 
intravenously injected with 12 × 107 splenocytes from MHC-
mismatched B6 or B6-Ly5.1 donors on day 0. In this model, 
cytopenia mediated by donor T cell attack of BM is the pri-
mary cause of death in GVHD (Via et al., 1987). Injection of 
R-Spo1 did not impact the mortality or morbidity caused by 
GVHD (Fig. 5, A and B), donor T cell expansion (Fig. 5 C), 
Figure 4.  R-Spo1 modulated systemic GVHD. B6D2F1 mice were transplanted with 5 × 106 TCD BM cells with or without 2 × 106 T cells from B6 donors 
on day 0 after 15 or 12 Gy TBI. R-Spo1 (200 µg/day) or control was injected from day 3 to 1 and day 1–3 after BMT. (A and B) Survival (A) and clinical 
GVHD scores (B; means ± SE) are shown. TCD non-GVHD controls (n = 6), allogeneic controls with 15 Gy (n = 11) or 12 Gy TBI (n = 15), and R-Spo1 with  
15 Gy (n = 13) or 12 Gy TBI (n = 15) are shown. Data from three independent experiments were combined. (C) Numbers of CD4+CD8+ double-positive thymo-
cytes 7 wk after BMT (TCD, n = 3; control, n = 5; R-Spo1, n = 5). Data are representative of two similar experiments and are shown as means ± SD. (D) Repre-
sentative histological findings of the small intestine, liver, and skin. Arrowheads indicate mononuclear cell infiltration in bile ducts and portal triads. Bars:  
(left and right) 100 µm; (middle) 50 µm. (E–G) Pathology scores of the small intestine (E) and liver (F) harvested on day 7 and those of the skin (G) harvested  
7 wk after BMT after 12 Gy TBI (TCD, n = 3; control, n = 5; R-Spo1, n = 5). Data are representative of two similar experiments and are shown as means ± SD. 
(H) R-Spo1 was intravenously injected for six doses at different schedules after 15 Gy TBI and BMT. Survival after BMT: TCD non-GVHD controls (n = 5), allo-
geneic controls (n = 17), and R-Spo1 day 3 to 1 and day 1–3 (D-3 to D+3; n = 11), day 6 to 1 (D−6 to D−1; n = 14), or day 1–6 (D+1 to D+6; n = 11) 
are shown. Data from three independent experiments were combined. *, P < 0.05 compared with allogeneic controls.JEM VOL. 208, February 14, 2011 
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(Kim et al., 2005) and confirming recent observations that 
R-Spo1 enhances the proliferation of cycling ISCs via the Wnt 
signaling pathway (Bhanja et al., 2009; Sato et al., 2009).
Administration of R-Spo1 has been shown to mediate 
protection  against  radiation  colitis,  which  is  evident  from 
studies in mouse models with chemotherapy- or radiation-
induced mucositis and gut injury (Kim et al., 2005; Zhao   
et al., 2007, 2009; Bhanja et al., 2009). Our results suggest that 
R-Spo1–mediated protection of ISCs could be primarily re-
sponsible for the protection of the GI tract from radiation,   
as has been suggested in a recent study (Bhanja et al., 2009). 
Furthermore, we have shown that brief administration of   
R-Spo1 suppresses systemic GVHD after allogeneic BMT by a 
mechanism dependent on the repair of conditioning-induced 
GI tract injury. Experimental and clinical studies have sug-
gested that GI tract damage resulting from both pretransplant 
conditioning regimens and GVHD plays a central role in in-
creasing GVHD severity (Hill et al., 1997; Hill and Ferrara, 
2000; Ferrara et al., 2003). Disruption of the GI mucosal bar-
rier facilitates the translocation of immunostimulatory micro-
bial products such as LPS into the systemic circulation (Hill   
et al., 1997; Cooke et al., 1998, 2001; Hill and Ferrara, 2000). 
LPS then stimulates mononuclear cells primed by donor   
T cell IFN- to produce large amounts of inflammatory cyto-
kines such as TNF and IL-1 and augments donor T cell acti-
vation, thereby potentiating both inflammatory and cellular 
effectors of GVHD (Nestel et al., 1992; Cooke et al., 1998, 
2001). The administration of R-Spo1 protected against GI 
tract damage, leading to the fortification of GI tract mucosal 
barrier functions and reduction of the subsequent inflamma-
tory  milieu. An  inflammatory  environment  would  have   
further enhanced donor T cell activation (Nestel et al., 1992; 
Hill et al., 1997; Cooke et al., 1998), and R-Spo1 treatment 
enigma because of the lack of specific markers. In this study, 
we discovered that pretransplant TBI damaged Olfm4+ ISCs 
in the crypts; however, the ISCs rapidly recovered and re-
stored the normal architecture of the small intestine within   
1 wk. With development of acute GVHD, the process of ISC 
recovery was inhibited, and prolonged and profound intesti-
nal damage was induced after allogeneic BMT. These obser-
vations are well in line with those from a previous study   
of sequential rectal biopsies from patients undergoing allo-
geneic BMT (Epstein et al., 1980). Severe crypt degeneration 
was noted in all biopsies taken soon after BMT, probably be-
cause of the conditioning regimen. These changes persisted 
when acute GVHD was present but disappeared in patients 
who did not show clinical evidence of GVHD (Epstein et al., 
1980). The current study thus affirms the long-held assump-
tion that ISCs may be targets for immune responses associated 
with GVHD (Sale et al., 1979; Epstein et al., 1980; Mowat 
and Socie, 2004).
We have previously demonstrated that R-Spo1 induces 
rapid onset of epithelial proliferation in the intestine by stim-
ulating Wnt signaling and protects against chemotherapy- 
induced colitis (Kim et al., 2005). However, owing to the lack 
of specific ISC markers it was unclear whether this effect   
was caused by the direct effect of R-Spo1 on ISCs. The current 
study shows that administration of R-Spo1 up-regulates the 
expression of Wnt target genes such as murine Axin2, Ascl2, 
and Lgr5. Ascl2 is a critical transcriptional factor involved in 
controlling the fate of ISCs in adults (van der Flier et al., 
2009b), and Lgr5 marks ISCs (Barker et al., 2007, 2008). Olfm4 
is not a Wnt target gene but a highly specific and robust 
marker for Lgr5+ ISCs (van der Flier et al., 2009a,b). We found 
that R-Spo1 stimulated proliferation of Olfm4+ ISCs, thus 
taking further the observations from our previous study   
Figure 5.  R-Spo1 failed to attenuate GVHD in unirradiated host. Unirradiated B6D2F1 mice were transplanted with 12 × 107 splenocytes from 
syngeneic or allogeneic B6 donors. R-Spo1 (200 µg/day) or control was administered from day 3 to 1 and day 1–3 after BMT. (A and B) Survival (A) 
and clinical GVHD scores (B; mean ± SE) are shown. Syngeneic controls (Syn; n = 3), allogeneic controls (control; n = 12), and R-Spo1 (n = 12) are shown. 
Data from two independent experiments were combined. (C–E) Numbers of donor CD4+ and CD8+ T cells in the spleen (C), CD4+CD8+ double-positive 
thymocytes (D), and a complete blood count (E) on day 14 (Syn, n = 3; control, n = 4; R-Spo1, n = 4) are shown. Data are representative of two indepen-
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Panoskaltsis-Mortari  et  al.,  1998;  Krijanovski  et  al.,  1999;   
Teshima et al., 1999; Hill and Ferrara, 2000). An intensified 
conditioning regimen plays a critical role in controlling leu-
kemia, but conditioning-related toxicity, particularly of the 
GI tract, limits the application of this curative therapy. Re-
duced intensity regimens have also been developed to explore 
the use of this therapy in older leukemic patients; however, 
better control of leukemia requires intensified conditioning 
in high-risk patients (Kahl et al., 2007). Thus, strategies to 
protect the GI tract from conditioning-related toxicity may 
allow safer application of intensified conditioning for con-
trolling leukemia. Such a strategy has been tested in previous   
studies using IL-11 or keratinocyte growth factor. However,   
it is unfortunate that patients receiving IL-11 displayed severe 
fluid retention and early mortality (Antin et al., 2002), while 
keratinocyte growth factor failed to reduce conditioning   
regimen–mediated diarrhea (Blazar et al., 2006), thus making it 
impossible to further test the proposed strategy. R-Spo1 use is 
highly promising because of its direct, specific, and potent   
effects on ISCs; therefore, brief treatment with R-Spo1 may 
be used as an effective adjunct to clinical regimens of GVHD 
prophylaxis. This study presents a novel combined strategy for 
the rescue of both hematopoietic stem cells and ISCs in clini-
cal medicine. Such a strategy may also be useful for treatment 
of other solid tumors and accidentally or intentionally irradi-
ated victims, in whom damage to BM and the GI tract is a se-
rious problem.
MATERIALS AND METHODS
Mice and reagents. Female B6 (H-2b, CD45.2+) and B6D2F1 (H-2b/d, 
CD45.2+) mice were purchased from Charles River, and B6-Ly5.1 (H-2b, 
CD45.1+) mice were obtained from the Jackson Laboratory. Mice were main-
tained as previously described (Teshima et al., 2002a). All animal experiments 
were performed under the auspices of the Institutional Animal Care and   
Research Advisory Committee. Recombinant human R-Spo1 was produced   
in CHO cells and purified as previously described (Zhao et al., 2007).
BMT. Mice were transplanted as previously described (Teshima et al., 2002a). 
In brief, after lethal TBI (x ray) delivered in two doses at 4-h intervals, 
B6D2F1 mice were intravenously injected with 5 × 106 TCD BM cells with 
or without 2 × 106 splenic T cells on day 0. Isolation of T cells and T cell de-
pletion were performed using the T cell isolation kit and anti-CD90 micro-
beads,  respectively,  and  AutoMACS  (Miltenyi  Biotec)  according  to  the 
manufacturer’s instructions. In some experiments, unirradiated B6D2F1 mice 
were intravenously injected with 12 × 107 splenocytes.
Assessment  of  GVHD.  Survival  after  BMT  was  monitored  daily,  and   
the degree of clinical GVHD was assessed weekly by a scoring system that 
sums changes in five clinical parameters: weight loss, posture, activity, fur   
texture, and skin integrity (maximum index = 10) as described previously 
(Teshima et al., 2002a). Acute GVHD was also assessed by detailed histopath-
ological  analysis  using  a  semiquantitative  scoring  system  (Teshima  et  al., 
2002a). Pictures from tissue sections were taken at room temperature using a 
digital camera (ProgRes 3012 mF; Jenoptik) mounted on a microscope 
(BX51; Olympus) and analyzed using a ProgRes PlugIn for PCI software 
version 5.0 (Jenoptik).
Flow cytometric analysis. mAbs used were FITC-, PE-, Cy5 PE–, or   
allophycocyanin-conjugated  or  biotinylated  anti–mouse TCR-,  IFN-, 
CD4, CD8, CD25, CD45.1, CD45.2, CD44, CD62L, CD69, and B220 (BD), 
was also found to significantly reduce donor T cell proliferation 
and activation. As a result, brief administration of R-Spo1   
modulates not only intestinal GVHD but also systemic GVHD.   
This study thus demonstrates for the first time that ISC dam-
age plays a critical role in the exaggeration of GVHD.
The protective effects of R-Spo1 were not observed after 
allogeneic BMT in the absence of a conditioning regimen, thus 
suggesting a mechanism dependent on repair of conditioning-
induced GI tract injury. In addition, R-Spo1 may act through 
different mechanisms before and after TBI; it protects best 
against  systemic  GVHD  when  administered  before  and   
after transplantation. Treatment with R-Spo1 before TBI ex-
panded ISCs, suggesting an increased number of surviving 
ISCs that play a pivotal role in the regeneration of intestinal 
epithelium after injury. Additional administration of R-Spo1 
posttransplant may further enhance proliferation and differ-
entiation of the surviving ISCs, thereby allowing the regener-
ation of intestinal epithelium and fortification of mucosal 
barrier functions to suppress subsequent inflammatory milieu.   
It has been shown that a single ISC is sufficient for the recon-
stitution of a crypt-villus unit (Sato et al., 2009).
Reduction in the activation of donor T cells after BMT 
did not appear to be caused by the direct effect of R-Spo1 on 
T cells. A recent study has shown that -catenin–transduced 
CD4+CD25+ T reg cells survive longer than control cells, 
whereas -catenin–transduced CD4+ T cells become anergic 
(Ding et al., 2008). Wnt signaling arrests effector T cell differ-
entiation by generating CD8+ memory stem cells (Gattinoni 
et al., 2009). However, such changes were not apparent after 
BMT in our study. Wnt signaling is also important for hema-
topoiesis (Reya and Clevers, 2005); however, brief administra-
tion of R-Spo1 did not affect hematopoietic reconstitution 
after TCD BMT (unpublished data). We thus believe that   
R-Spo1 may preferentially stimulate ISCs rather than hemato-
poietic and T cells, as R-Spo1 transgenic mice show intestinal 
epithelial hyperplasia without any effects on lymphohemato-
poietic development (Kim et al., 2005). Alternately, such brief 
administration of R-Spo1 may not be sufficient to affect both 
the immune system and hematopoiesis. Wnt signaling has   
also been implicated in the pathogenesis of various tumors 
such as colon cancer and leukemia (Reya and Clevers, 2005; 
Román-Gómez et al., 2007). However, the incidence of tumori-
genesis did not increase in R-Spo1 transgenic mice (Kim et al., 
2006), and long-term treatment with R-Spo1 did not promote 
tumor xenograft growth in immunodeficient mice inoculated 
with various human colorectal tumor cell lines (Zhao et al., 
2009). It thus follows that although caution should be exer-
cised, it is unlikely that brief administration of R-Spo1 en-
hances tumorigenesis or the growth of preexisting tumors.
In summary, we found that ISCs are targets for GVHD 
and that protection of ISCs by R-Spo1 significantly im-
proved the outcome of BMT by reducing systemic GVHD 
severity. By documenting that ISC damage is the key to   
this process, these results extend previous observations that 
the GI tract is not only a target organ for GVHD but also a 
crucial amplifier of systemic GVHD severity (Hill et al., 1998; JEM VOL. 208, February 14, 2011 
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shows that R-Spo1 has no effects on proliferation and effector differen-
tiation of T cells in response to CD3 or alloantigen stimulation in vitro.   
Online supplemental material is available at http://www.jem.org/cgi/content/ 
full/jem.20101559/DC1.
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